Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial
Elsevier ·
The publisher did not provide an abstract — full text is available via the link below.
Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial. // eClinicalMedicine. – URL: https://www.sciencedirect.com/science/article/pii/S2589537026005389?dgcid=rss_sd_all
Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial. eClinicalMedicine. https://www.sciencedirect.com/science/article/pii/S2589537026005389?dgcid=rss_sd_all
“Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial.” eClinicalMedicine.
@article{article93724,
title = {Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial},
journal = {eClinicalMedicine},
url = {https://www.sciencedirect.com/science/article/pii/S2589537026005389?dgcid=rss_sd_all}
}